Figure 1.
Overall survival (OS) and progression-free survival (PFS) of non-small cell lung cancer (NSCLC) patients treated with first-line pembrolizumab stratified by GRImT0 (a,b), GRImT1 (c,d) and GRImΔ (e,f) values.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.